Kinaset Therapeutics

Kinaset Therapeutics develops inhaled therapies for respiratory diseases. Lead candidate frevecitinib is an anti-inflammatory for severe asthma.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Series B
Initial Investment Year
2026
Kinaset Hover Image